Zhejiang Huahai Pharmaceutical (600521.SH): Mesalazine enteric-coated tablets obtain drug registration certificate.

17:02 03/04/2026

Huahai Pharmaceutical (600521.SH) announced that the company has recently received the "Drug Registration Certificate" for the mesalazine enteric-coated tablets issued by the National Medical Products Administration. Mesalazine enteric-coated tablets are used for the treatment of: 1. Ulcerative colitis, including treatment during acute attacks and maintenance therapy to prevent recurrence; 2. Treatment during acute attacks of Crohn's disease.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company has recently received the "Drug Registration Certificate" for Mesalazine Enteric-coated Tablets issued by the National Medical Products Administration. Mesalazine Enteric-coated Tablets are used for: 1. Treatment of ulcerative colitis, including treatment during acute attacks and maintenance therapy to prevent relapse; 2. Treatment of acute attacks of Crohn's disease.

Industrial: Market fluctuations intensify. How are various types of funds moving?

Chairman Zheng Jiachun increased his holding of CHOW TAI FOOK (01929) by 30,000 shares at a price of approximately HK$10.76 per share.

Chairman Pan Binze increases his holdings in TEXWINCA HOLD (00321) by 2.76 million shares at a price of approximately 1.21 Hong Kong dollars per share.

Industrial: Market fluctuations intensify. How are various types of funds moving?

Chairman Zheng Jiachun increased his holding of CHOW TAI FOOK (01929) by 30,000 shares at a price of approximately HK$10.76 per share.

Chairman Pan Binze increases his holdings in TEXWINCA HOLD (00321) by 2.76 million shares at a price of approximately 1.21 Hong Kong dollars per share.